coronary intervention News
-
Corindus Announces New Clinical Data Showing 20 Percent Reduction in Patient Radiation Exposure with Robotic-assisted Intervention
Corindus, a Siemens Healthineers company and leading developer of precision vascular robotics, announced today that Circulation: Cardiovascular Interventions has published clinical results from a comparative study between robotic percutaneous coronary intervention (PCI) and manual PCI. Findings from the study show robotic PCI with the CorPath GRX System reduces patient exposure to radiation by ...
-
Miracor announces PiCSO Therapy clinical data to be presented at EuroPCR 2018
Miracor Medical SA today announced that new clinical data of the PiCSO® Impulse System for the treatment of STEMI patients will be presented during the EuroPCR conference in Paris, May 21st - 24th 2018. The PiCSO clinical results will be presented during two different sessions, including a Hotline session: Thursday May 24th @ 11:03 in the "Hotline Coronary Intervention" session, Room ...
-
Supira Medical, A Shifamed Portfolio Company, Closes $35M in Series B Financing
Company Appoints Seasoned Medtech Executive as President and CEO CAMPBELL, Calif., March 5, 2020 – Supira Medical, formed by Shifamed as part of its medical innovation hub, announced today the closing of $35M in Series B financing. Officially closed on February 25, the financing was led by Cormorant Asset Management with participation from The Capital Partnership (TCP), 415 CAPITAL, AMED ...
-
Osprey Medical Receives US FDA Clearance for DyeVert™ Plus
Osprey Medical (ASX:OSP) today announced that it has received US FDA 510(k) clearance for its advanced DyeVert™ PLUS Contrast Reduction System. This new platform augments Osprey’s current technology with the capability to actively manage dye administration during coronary interventions. DyeVert PLUS received European CE Mark in 4Q 2016. The company further validated its dye savings ...
-
Shockwave Medical Initiates All-Female Coronary IVL Study
EMPOWER CAD is the First Prospective, Female-Only Study of Coronary Interventions Study Seeks to Confirm Benefits of Shockwave’s Coronary IVL in Females Who Historically Have Suffered Less Favorable Clinical Outcomes than Male Patients with Traditional Therapies Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely ...
-
CathWorks FFRangio System Receives Regulatory Approval in Japan
CathWorks today announced the approval of The CathWorks FFRangio™ System by the Japan’s Ministry of Health, Labour and Welfare (MHLW). The CathWorks FFRangio System is a non-invasive diagnostic technology that is used at the time of a routine angiography. The CathWorks FFRangio System transforms routine angiogram images into objective and comprehensive physiology information, ...
By CathWorks
-
Miracor Medical announces PiCSO presentations during PCR e-Course
Miracor Medical SA announces today that an update about PiCSO therapy will be presented during the upcoming PCR e-Course which will be held on June 25, 26 and 27. PiCSO therapy (Pressure-Controlled Intermittent Coronary Sinus Occlusion) is delivered by interventional cardiologists during the primary PCI (Percutaneous Coronary Intervention) procedure in patients experiencing anterior ST-elevated ...
-
Puzzle Medical to Present at TCT 2022 Its First-in-Human Study Results for the ModulHeart™
Montreal-based Puzzle Medical Devices Inc. (PMD) developed a percutaneous heart pump designed to support cardiac and renal function in patients with advanced heart failure (HF). PMD announced it will present its first-in-human results for the ModulHeartTM in the following session during the Transcatheter Cardiovascular Therapeutics (TCT) meeting held September 16-19, 2022 at the Boston Convention ...
-
Miracor Medical closes final tranche of Series-D bringing the round to 30€M
Miracor Medical SA (Miracor Medical) today announced the final closing of the Series D financing round of €30M. The Series D capital will be used to further develop and commercialize the PiCSO® Impulse System. The Series-D round was led by Ming Capital (Shenzhen, China) and co-led by a strategic investor. Participating new investors include Belgian alternative investment fund Quest for ...
-
Puzzle Medical to Present at AHA 2022 its First-in-Human Study Results
Puzzle Medical Devices Inc. is delighted to announce its first-in-human results for the ModulHeart have been presented at the prestigious American Heart Association (AHA) meeting held November 5–7, 2022 at the McCormick Place Convention Center in Chicago, IL. Montreal-based Puzzle Medical Devices Inc. (PMD) developed a percutaneous heart pump designed to support cardiac and renal function ...
-
Corindus Completes First-Ever, Transcontinental Simulated Telerobotic Percutaneous Coronary Intervention Procedures Over 5G, Fiber, and Public Internet Networks
Corindus, a Siemens Healthineers company and a leading developer of precision vascular robotics, announced today it has completed the first multi-city, transcontinental percutaneous coronary intervention (PCI) simulations in the United States over three network connection types – 5G wireless, dedicated fiber, and commercial public internet networks. Interventional cardiologist Ryan Madder, ...
-
Miracor Medical awarded CE Mark for PiCSO Impulse Catheter and Console
Miracor Medical SA (Miracor Medical) has announced the award of the CE Mark for its latest generation of PiCSO Impulse Catheter and PiCSO Impulse Console, which is indicated for the treatment of anterior STEMI patients. The new system features improvements in ease of use. PiCSO therapy is delivered by interventional cardiologists during the primary PCI (Percutaneous Coronary Intervention) ...
-
AKI Burden of Illness Data Presented at Premier Breakthroughs Conference
Osprey Medical (ASX: OSP) today announces that Dr Anand Prasad, M.D., Director of the Cardiac Catheterization Laboratory at University Health System and Associate Professor of Medicine at UT Health Science Centre at San Antonio, Texas presented the Acute Kidney Injury (AKI) Burden of Illness Study1 at the Premier Breakthroughs 2019 Conference and Exhibition in Nashville, Tennessee on behalf of ...
-
Miracor Medical granted FDA Breakthrough Device Designation for the PiCSO therapy
Miracor Medical SA (Miracor Medical) has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its PiCSO Impulse System for treatment of STEMI patients. The FDA Breakthrough Device designation is intended to speed time to market for treatments of life-threatening or irreversibly debilitating diseases or conditions and recognizes the novelty of the PiCSO ...
-
Infraredx, a Nipro Company, Announces Enrollment of First Patient in EXPANSE PTCA study.
Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced today the enrollment of the first patient in its EXPANSE PTCA study (NCT04985773) at the Cardiology Associates of North Mississippi in Tupelo, Mississippi. The study will be conducted in the United States with the objective to evaluate safety and effectiveness of the Lacrosse NSE ...
-
CathWorks Adds Vice President of Global Marketing to Leadership Team
CathWorks announced that Ramin Mousavi has joined CathWorks as Vice President of Global Marketing & Strategy. Mr. Mousavi, an experienced cardiovascular marketer, will take responsibility for the CathWorks FFRangio™ System U.S. clinical and commercial launch and direct future expansion into other global markets. Mr. Mousavi has over 15 years of global marketing, strategy, product ...
By CathWorks
-
B. Braun Interventional Systems Inc., an Affiliate of B. Braun Medical Inc., and Infraredx, a Nipro Company, Announce Strategic U.S. Collaboration to Execute the IDE Clinical Trial for the SeQuent Please ReX Drug Coated PTCA Balloon Catheter
B. Braun Interventional Systems Inc. (BIS) announced today that they will collaborate with Infraredx, a Nipro Company, to accelerate the U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) clinical trial for the B. Braun SeQuent Please ReX Drug Coated PTCA Balloon Catheter, which received FDA Breakthrough Device Designation in late 2019. This announcement furthers the ...
-
Corindus Named to Fast Company’s “Most Innovative” List for 2021 Amid Global Expansion
Corindus, A Siemens Healthineers Company and one of the leading developers of precision vascular robotics, announced today it has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2021, earning the No. 5 spot in the robotics category. The award recognizes Corindus and its robotic platform with developmental remote technology for its ...
-
Robocath successfully completes first robotic coronary angioplasties in Belgium
Robocath, a company that designs, develops and commercializes cardiovascular robotic platforms for the treatment of vascular diseases, today announces the successful completion of first five robotic coronary angioplasties in Belgium. The Percutaneous Coronary Interventions (PCI) were performed on April 8 and 13 by Prof. Stefan Verheye, a recognized and highly experienced interventional ...
By Robocath
-
Puzzle Medical Announces the Successful Completion of its First-in-Human Study with its ModulHeart
Montreal-based Puzzle Medical Devices Inc., announced today the successful completion of the company’s ?rst-in-human study to evaluate the performance of its ModulHeart percutaneous heart pump designed to reduce cardiac afterload and improve renal perfusion in patients with advanced heart failure (HF). Four patients had ModulHeart deployed to provide circulatory support while undergoing ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you